Heparin versus bivalirudin for non-primary percutaneous coronary intervention: A post-Hoc analysis of the CPORT-E trial.
Matthew J CzarnyChao-Wei HwangDaniel Q NaimanCynthia C LemmonRani K HasanThomas WangThomas AversanoPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
In patients undergoing non-primary PCI at hospitals without on-site cardiac surgery, bivalirudin was associated with a decreased risk of in-hospital bleeding requiring transfusion and an increased risk of in-hospital MI compared to heparin. © 2017 Wiley Periodicals, Inc.
Keyphrases
- percutaneous coronary intervention
- cardiac surgery
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- coronary artery disease
- antiplatelet therapy
- patients undergoing
- coronary artery bypass grafting
- atrial fibrillation
- healthcare
- venous thromboembolism
- acute kidney injury
- growth factor
- acute care
- coronary artery bypass
- study protocol
- clinical trial
- phase iii
- emergency department
- randomized controlled trial
- left ventricular
- open label